Skip to main content
    H

    Humacyte Inc (HUMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    -0.02 (-3.24%)

    Market Cap: $155.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(11/23)
    Avg Surprise
    +16.10%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.11 - -$0.05
    8 analysts
    Revenue Consensus
    $2.15M
    Range$1.96M - $2.42M
    7 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.07
    Range-$0.09 - -$0.05
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08+2.3%
    60d ago-$0.07-4.7%
    30d ago-$0.07-4.7%
    7d ago-$0.07-4.7%
    Current-$0.07
    Revenue Consensus
    $2.13M
    Range$1.23M - $3.40M
    4 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-4574.00%
    ROE-1424.00%ROIC-60.48%
    Financial Health
    Debt/Equity3.65xInterest Coverage-1.99x
    Current Ratio3.34xQuick Ratio3.11x
    Trading Statistics
    Beta2.68Avg Volume4.81M
    52-Week High$1.5252-Week Low$0.34

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 9.6% above its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 56.8, in the neutral range between 30 and 70.

    Moving Averages

    SMA 10$0.51
    SMA 20$0.47
    SMA 50$0.49
    SMA 200$0.78
    EMA 10$0.52
    EMA 20$0.49
    EMA 50$0.51
    EMA 200$0.80

    MACD

    Line: 0.02Signal: 0.00Hist: 0.02

    ADX

    ADX: 23.2+DI: 26.5-DI: 16.8

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$0.44

    Bollinger Bands

    Upper Band$0.60
    Lower Band$0.33
    %B Position5934%(Upper)
    Band Width0.77

    RSI (14-Day)

    Neutral
    56.8

    Momentum Oscillators

    Stoch %K73.3
    Stoch %D81.2
    Williams %R-36.6
    ROC (10d)35.7%
    Momentum0.14
    CCI (20d)99.7
    MFI (14d)70.4

    Volatility Measures

    ATR (14d)$0.06(10.7%)
    StdDev (20d)0.07
    Hist Vol151.0%(High)

    Volume Flow

    VWAP$0.55
    OBV-321.2M
    AD Line-329.3M
    CMF (20d)0.082

    Volume Metrics

    Avg Vol (20d)4.8M
    Vol Ratio0.6x
    VWMA (20d)$0.48

    Pivot Points

    R3$0.68
    R2$0.64
    R1$0.60
    Pivot Point$0.57
    S1$0.53
    S2$0.49
    S3$0.45

    Advanced Oscillators

    TSI11.52
    Ultimate Osc56.0
    KST94.62

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about HUMA

    News

    HUMA Valuation

    Humacyte (HUMA) trades at 35.8x forward earnings.

    Forward P/E
    35.8x
    P/B
    8.3x
    HUMA valuation multiples

    HUMA Profitability: Margins, ROIC and FCF

    Humacyte (HUMA) has a gross margin of -462.6%, an operating margin of -4574.0% and a net margin of 0.0%. It posts -60.5% ROIC and a -3697.0% FCF margin.

    Gross margin
    -462.6%
    Operating margin
    -4574.0%
    Net margin
    0.0%
    ROIC
    -60.5%
    ROE
    -1424.0%
    FCF margin
    -3697.0%
    HUMA financial statements

    The companies most similar to Humacyte (HUMA) include TuHURA Biosciences, Whitehawk Therapeutics and Unicycive Therapeutics.

    Sector: Healthcare

    Companies most similar to Humacyte

    HUMA Analyst Ratings

    Humacyte (HUMA) has a Buy consensus from 6 analysts: 4 Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    3
    Hold
    2
    Sell
    0
    Strong Sell
    0
    HUMA stock forecast

    HUMA Bull Case vs Bear Case

    Bull case

    • HUMA grew quarterly revenue 36.5% year over year.
    • 66.7% of HUMA's analyst ratings are Buy or Strong Buy.

    Bear case

    • HUMA has a debt-to-equity ratio of 3.6x.

    HUMA Earnings: Beat Rate and Next Report

    Humacyte (HUMA) beat the EPS estimate in 5 of the last 8 quarters (62.5%). Its next report is expected on Mar 25, 2027.

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    22.3%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.07
    HUMA earnings history

    HUMA Earnings Date

    HUMA reports Mar 25, 2027. The date is estimated.

    HUMA Earnings Call

    The latest HUMA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    HUMA ETF Holders

    See insider activity

    Updated Nov 10, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About HUMA

    When does HUMA report earnings?

    Humacyte Inc (HUMA) is expected to report earnings on Mar 25, 2027.

    Does HUMA pay dividends?

    Humacyte Inc (HUMA) does not currently pay a regular dividend.

    What is HUMA's market cap?

    Humacyte Inc (HUMA) has a market capitalization of $155.12M with a current stock price of $0.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.